REFRACTORY CLASSIC HODGKIN LYMPHOMA
Clinical trials for REFRACTORY CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug cocktail shows promise for tough hodgkin lymphoma cases
Disease control OngoingThis study is for people with Hodgkin lymphoma that has come back or not responded to prior treatments. It tests a combination of three drugs: two that boost the immune system (ipilimumab and nivolumab) and one that targets and kills cancer cells (brentuximab vedotin). The goal i…
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 10:11 UTC
-
Two-Drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped resp…
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC